The European Gaucher Alliance: a survey of member patient organisations’ activities, healthcare environments and concerns
Open Access
- 2 September 2014
- journal article
- research article
- Published by Springer Nature in Orphanet Journal of Rare Diseases
- Vol. 9 (1) , 1-14
Abstract
The European Gaucher Alliance (EGA) was established in 1994 and constituted in 2008 as an umbrella group supporting patient organisations for Gaucher disease. Every two years, the EGA conducts a questionnaire survey of member associations to help develop its priorities and annual work programme. Results of the latest survey are presented. Between June 2012 and April 2013, the 36 members and associate members of the EGA were asked to complete a questionnaire detailing membership numbers, disease specific treatments used by patients, means of access to treatment, availability of treatment centres and home infusions, sources of support for patients with Gaucher disease, patient organisations’ activities, collaborations, funding sources and any issues of concern. Questionnaires completed in 2012 were revised in January 2013 and responses analysed between July and September 2013. Thirty three members returned data on one or more questions. Findings identified inequalities in access to treatment both within and between members’ countries. Three of 27 countries, for which data were available, relied totally on humanitarian aid for treatment and 6% of untreated patients in 20 countries were untreated because of funding issues, a situation many feared would worsen with deteriorating economic climates. Access to treatment and reimbursement represented 45% of members’ concerns, while 35% related to access to specialist treatment centres, home infusions and doctors with expertise in Gaucher disease. Member associations’ main activities centred on patient support (59% of responses) and raising awareness of Gaucher disease and patients’ needs amongst the medical community, government and healthcare decision makers and the general public (34% of responses). Twenty one (78% of respondents) indicated they were the only source of help for Gaucher disease patients in their country. For many, activities were constrained by funds; two members had no external funding source. Activities were maximised through collaboration with other patient organisations and umbrella organisations for rare diseases. The survey provided a snapshot’ of the situation for patients and families affected by Gaucher disease, helping the EGA direct its activities into areas of greatest need.Keywords
This publication has 39 references indexed in Scilit:
- The legal imperative for treating rare disordersOrphanet Journal of Rare Diseases, 2013
- Long‐term clinical outcomes in type 1 Gaucher disease following 10 years of imiglucerase treatmentJournal of Inherited Metabolic Disease, 2012
- Involvement of Patient Organisations in Research and Development of Orphan Drugs for Rare Diseases in EuropeMolecular Syndromology, 2012
- Did the Temporary Shortage in Supply of Imiglucerase Have Clinical Consequences? Retrospective Observational Study on 34 Italian Gaucher Type I Patients2012
- Gaucher disease: clinical profile and therapeutic developmentsBiologics: Targets and Therapy, 2010
- Improvement in hematological, visceral, and skeletal manifestations of Gaucher disease type 1 with oral eliglustat tartrate (Genz-112638) treatment: 2-year results of a phase 2 studyBlood, 2010
- Peripheral neuropathy in adult type 1 Gaucher disease: a 2-year prospective observational studyBrain, 2010
- Neuronopathic Gaucher disease: demographic and clinical features of 131 patients enrolled in the International Collaborative Gaucher Group Neurological Outcomes SubregistryJournal of Inherited Metabolic Disease, 2010
- Phenotypic heterogeneity of N370S homozygotes with type I Gaucher disease: An analysis of 798 patients from the ICGG Gaucher RegistryJournal of Inherited Metabolic Disease, 2008
- Management of non‐neuronopathic Gaucher disease with special reference to pregnancy, splenectomy, bisphosphonate therapy, use of biomarkers and bone disease monitoringJournal of Inherited Metabolic Disease, 2008